"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 8 | 13 | 21 |
| 1995 | 4 | 18 | 22 |
| 1996 | 5 | 16 | 21 |
| 1997 | 2 | 16 | 18 |
| 1998 | 4 | 21 | 25 |
| 1999 | 6 | 14 | 20 |
| 2000 | 2 | 23 | 25 |
| 2001 | 3 | 18 | 21 |
| 2002 | 6 | 25 | 31 |
| 2003 | 9 | 25 | 34 |
| 2004 | 12 | 23 | 35 |
| 2005 | 3 | 25 | 28 |
| 2006 | 3 | 18 | 21 |
| 2007 | 6 | 33 | 39 |
| 2008 | 6 | 26 | 32 |
| 2009 | 4 | 44 | 48 |
| 2010 | 3 | 36 | 39 |
| 2011 | 5 | 26 | 31 |
| 2012 | 6 | 18 | 24 |
| 2013 | 4 | 32 | 36 |
| 2014 | 5 | 42 | 47 |
| 2015 | 7 | 39 | 46 |
| 2016 | 6 | 21 | 27 |
| 2017 | 7 | 27 | 34 |
| 2018 | 8 | 28 | 36 |
| 2019 | 3 | 30 | 33 |
| 2020 | 6 | 28 | 34 |
| 2021 | 6 | 29 | 35 |
| 2022 | 1 | 30 | 31 |
| 2023 | 1 | 23 | 24 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024 Mar 12; 8(5):1128-1136.
-
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 Apr; 99(4):562-569.
-
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Feb; 204(1):123-132.
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023 11 28; 7(22):7141-7150.
-
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood. 2023 11 23; 142(21):1784-1788.
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023 Dec; 24(12):1359-1374.
-
Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 01; 59(1):76-84.
-
Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Transplant Cell Ther. 2024 Jan; 30(1):114.e1-114.e16.
-
Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. Leuk Lymphoma. 2023 Dec; 64(14):2258-2268.
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 09; 29(9):548-555.